Table 2.

Univariate and multivariate analysis for OS in advanced NSCLC PDL1 TPS ≥ 50% patients treated with first-line pembrolizumab.

Variable	HR (95% CI) Univariate Analysis	p-Value	HR (95% CI) Multivariate Analysis	p-Value
Age	1.000 (0.990–1.010)	0.986
Sex
Female vs. Male	1.100 (0.917–1.321)	0.304
ECOG PS
0–1 vs. ≥2	2.051 (1.707–2.464)	<0.001	2.041 (1.699–2.453)	<0.001
Pembrolizumab Schedule
Q3W vs. Q6W	0.718 (0.458–1.124)	0.147	0.759 (0.485–1.190)	0.230